NSE · NATCOPHARM
Natco Pharma Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹597 Cr with net profit ₹75 Cr — a 12.5% net margin, versus 32.42% the period before.
Shareholding
As of 2026-09-30
- Promoter49.39%
- Public28.45%
- FII16%
- DII6.16%
4,04,135 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.59× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #22 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,20,963 Cr | 33.32 | 5.04 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,17,426 Cr | 24.05 | 4.33 | 18.59% | 16.09% |
| Laurus Labs Limited | ₹1,14,541 Cr | 104.74 | 21.61 | 16.77% | 15.04% |
| Cipla Ltd. | ₹1,10,032 Cr | 30.74 | 3.2 | 11.27% | 12.06% |
| Dr Reddys Laboratories Ltd. | ₹1,09,602 Cr | 39.15 | 2.82 | 7.21% | 8.49% |
| Mankind Pharma Limited | ₹1,03,175 Cr | 48.36 | 6.33 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹93,907 Cr | 24.84 | 2.48 | 9.25% | 10.7% |
| Lupin Limited | ₹89,392 Cr | 15.01 | 3.98 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹63,292 Cr | 20.28 | 6.02 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹61,684 Cr | 27.07 | 4.46 | 16.66% | 14.31% |
| Natco Pharma Ltd.(this company) | ₹15,533 Cr | 13.57 | 1.48 | 15.38% | 32.84% |
AI analysis
AI-generated · google/gemini-2.5-flashNatco Pharma Ltd. is listed with a market capitalization of Rs 17027 Cr. The company reported revenue of Rs 4784 Cr with a profit margin of 34.78%. The EPS stands at 79.2, and the debt-to-equity ratio is 0.05. The 52-week high for the share price was 1226.8, and the 52-week low was 789.
Positives
- +The company's profit margin is 34.78%.
- +Return on equity (ROE) is 15.38%, and return on capital employed (ROCE) is 15.3664%.
- +The debt-to-equity ratio is low at 0.05.
Negatives
- −The Price to Earnings (PE) ratio of 63.55 is high relative to the EPS of 79.2.
- −The dividend yield is 53, which is an unusually high figure.
- −No quarterly results have been disclosed since Mar 2026.
Financial Performance
Natco Pharma Ltd. recorded a revenue of Rs 4784 Cr with a revenue growth of 10.8%. The net profit reported for the Mar 2025 period was Rs 1885.4 Cr. For the Mar 2026 quarter, revenue was Rs 739.1 Cr with a net profit of Rs 267.9 Cr.
Profitability & Returns
The company's profit margin is 34.78%. Return on equity (ROE) is 15.38%, and return on capital employed (ROCE) is 15.3664%. The earnings per share (EPS) for the last reported period is 79.2.
Balance Sheet
Natco Pharma Ltd. maintains a book value of 514.83. The debt-to-equity ratio stands at 0.05, indicating a low level of debt relative to equity. This suggests a healthy capital structure for the company.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Natco Pharma Ltd. was 49.4195%. FIIs held 16.9877%, while DIIs held 5.621%. The public shareholding was 27.9718%. There are no promoter shares reported as pledged.
Data as of — price: 2026-10-27 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.